RNXT
MaterialsRenovoRx Inc
$0.89-0.04 (-4.14%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RNXT Today?
No stock-specific AI insight has been generated for RNXT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$40M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume286K
Avg Volume (10D)—
Shares Outstanding45.1M
RNXT News
20 articles- Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag EstimatesYahoo Finance·May 7, 2026
- RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETYahoo Finance·Apr 29, 2026
- RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingYahoo Finance·Apr 23, 2026
- Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingYahoo Finance·Apr 14, 2026
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa VasorumYahoo Finance·Apr 8, 2026
- RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026GlobeNewswire Inc.·Apr 1, 2026
- RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo Finance·Mar 31, 2026
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of EnrollmentYahoo Finance·Mar 26, 2026
- TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 24, 2026
- RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private PlacementYahoo Finance·Mar 23, 2026
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ETYahoo Finance·Mar 20, 2026
- RenovoRx Announces $10 Million at Market Private PlacementYahoo Finance·Mar 18, 2026
- CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 16, 2026
- Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 3, 2026
- RenovoRx advances RenovoCath adoption at U.S. cancer centersYahoo Finance·Feb 28, 2026
All 20 articles loaded
Price Data
Open$0.92
Previous Close$0.93
Day High$0.95
Day Low$0.89
52 Week High—
52 Week Low—
Fundamentals
Market Cap$40M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume286K
Avg Volume (10D)—
Shares Outstanding45.1M
About RenovoRx Inc
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—